Cutler Group’s Takeda Pharmaceutical TAK Stock Holding History

Cutler Group’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,300	Closed	-$4K	–	5193
2022 Q3	$4K	Buy	+4,300	New	+$59.8K	﹤0.01%	3851
2022 Q2	–	Sell	-4,900	Closed	-$11K	–	5657
2022 Q1	$11K	Buy	+4,900	New	+$71.9K	﹤0.01%	3555
2021 Q4	–	Sell	-1,300	Closed	-$1K	–	6048
2021 Q3	$1K	Buy	1,300 +900	+225%	+$15.1K	﹤0.01%	5439
2021 Q2	$1K	Buy	+400	New	+$6.81K	﹤0.01%	5429
2021 Q1	–	Sell	-5,500	Closed	-$23K	–	6259
2020 Q4	$23K	Hold	5,500	–	–	﹤0.01%	2587
2020 Q3	$24K	Hold	5,500	–	–	﹤0.01%	2334
2020 Q2	$27K	Hold	5,500	–	–	﹤0.01%	2179
2020 Q1	$40K	Sell	5,500 -12,800	-70%	-$232K	﹤0.01%	1868
2019 Q4	$28K	Buy	18,300 +2,000	+12%	+$38.3K	﹤0.01%	2008
2019 Q3	$66K	Buy	16,300 +300	+2%	+$5.19K	0.01%	1343
2019 Q2	$68K	Buy	+16,000	New	+$291K	0.01%	1332

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Cutler Group's TAK Position: Q1 2023 in Review

Cutler Group sold out of Takeda Pharmaceutical (TAK) in Q1 2023, closing a stake of 2,244 shares — an estimated $35.7K sold.

Cutler Group first reported a position in TAK in Q2 2019 and held it in 13 quarters. The position peaked at $385K in Q2 2019. 300 funds tracked by Wall St. Rank hold TAK as of Q1 2023.

Cutler Group reported no remaining Takeda Pharmaceutical position as of Q1 2023 after selling out during the quarter.
Cutler Group sold 2,244 Takeda Pharmaceutical shares in Q1 2023, an estimated $35.7K.
Cutler Group first reported a position in Takeda Pharmaceutical in Q2 2019 and held it in 13 quarters.
Cutler Group's Takeda Pharmaceutical position peaked at $385K in Q2 2019.
300 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.